A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer

Mike Mason, Óscar Lapuente-Santana, Anni S. Halkola, Wenyu Wang, Raghvendra Mall, Xu Xiao, Jacob Kaufman, Jingxin Fu, Jacob Pfeil, Jineta Banerjee, Verena Chung, Han Chang, Scott D. Chasalow, Hung Ying Lin, Rongrong Chai, Thomas Yu, Francesca Finotello, Tuomas Mirtti, Mikko I. Mäyränpää, Jie BaoEmmy W. Verschuren, Eiman I. Ahmed, Michele Ceccarelli, Lance D. Miller, Gianni Monaco, Wouter R. L. Hendrickx, Shimaa Sherif, Lin Yang, Ming Tang, Shengqing Stan Gu, Wubing Zhang, Yi Zhang, Zexian Zeng, Avinash Das Sahu, Yang Liu, Wenxian Yang, Davide Bedognetti, Jing Tang, Federica Eduati, Teemu D. Laajala, William J. Geese, Justin Guinney, Joseph D. Szustakowski, Benjamin G. Vincent, David P. Carbone

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Predictive biomarkers of immune checkpoint inhibitor (ICI) efficacy are currently lacking for non-small cell lung cancer (NSCLC). Here, we describe the results from the Anti–PD-1 Response Prediction DREAM Challenge, a crowdsourced initiative that enabled the assessment of predictive models by using data from two randomized controlled clinical trials (RCTs) of ICIs in first-line metastatic NSCLC.
Original languageEnglish
Article number190
JournalJournal of Translational Medicine
Volume22
Issue number1
Number of pages16
ISSN1479-5876
DOIs
Publication statusPublished - 21 Feb 2024
MoE publication typeA1 Journal article-refereed

Fields of Science

  • 3122 Cancers

Cite this